Patient Reports Benefit from Revolution Medicines’ Daraxonrasib as Oncologists Applaud Data but Biotech Stocks Fall

Leanna Stokes, diagnosed with metastatic pancreatic cancer in 2023, discussed how participating in Revolution Medicines’ clinical trial for daraxonrasib has affected her disease and life on the June 4, 2026 episode of STAT’s weekly biotech podcast The Readout LOUD.

The episode, hosted by Elaine Chen, Adam Feuerstein, and Allison DeAngelis, also covered data presented at last week’s American Society of Clinical Oncology meeting, where oncologists gave a standing ovation to a presentation on daraxonrasib. Biotech stocks performed badly during the week of the June 4, 2026 podcast.

The hosts examined the market reaction to Abivax’s ulcerative colitis data presented during the same period. The upcoming American Diabetes Association meeting was also discussed on the episode. The Readout LOUD is available on Apple Podcasts, Spotify, and other platforms.